Innovent and Daiichi Sankyo sign deal for Vanflyta in China

Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.

Vanflyta received approval in the country in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, as well as for maintenance monotherapy following consolidation chemotherapy.

The indication covers treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) as determined by an appropriate validated diagnostic test. Approval was based on data from the QuANTUM-First trial.

Innovent Biologics executive director and chief commercial officer Vivian Zhang said: “Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence, including TYVYT (sintilimab injection), Halpryza (rituximab injection), olverembatinib, Fucaso (Equecabtagene Autoleucel Injection), Jaypirca (pirtobrutinib), and the addition of Vanflyta will further enhance our synergistic offerings.”

“Vanflyta will be the 20th product in Innovent’s commercialised product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology.”

Daiichi Sankyo China president Michio Hayashi said: “The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China.

“By combining our research and development capabilities with Innovent’s commercial capabilities in China, we believe this collaboration can accelerate access to Vanflyta for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population.”

Last month, Innovent Biologics agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China.

The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review.